MA32300B1 - Anticorps anti-facteur d humanises et utilisations de ceux-ci - Google Patents

Anticorps anti-facteur d humanises et utilisations de ceux-ci

Info

Publication number
MA32300B1
MA32300B1 MA33342A MA33342A MA32300B1 MA 32300 B1 MA32300 B1 MA 32300B1 MA 33342 A MA33342 A MA 33342A MA 33342 A MA33342 A MA 33342A MA 32300 B1 MA32300 B1 MA 32300B1
Authority
MA
Morocco
Prior art keywords
antibodies
factor antibodies
treatment
humanizing anti
factor
Prior art date
Application number
MA33342A
Other languages
Arabic (ar)
English (en)
Inventor
Robert F Kelley
Henry Lowman
Lookeren Campagne Menno Van
Arthur J Huang
Charles M Winter
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40999836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32300(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA32300B1 publication Critical patent/MA32300B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps anti-facteur d, leurs séquences d'acide nucléique et d'acides aminés, les cellules et vecteurs qui portent ces anticorps et leur production et leur utilisation dans la préparation de compositions et de médicaments pour le traitement de maladies et de troubles associés à une activation du complément excessive ou incontrôlée. Ces anticorps sont utiles pour le diagnostic, la prophylaxie et le traitement d'une maladie.
MA33342A 2008-04-28 2010-11-11 Anticorps anti-facteur d humanises et utilisations de ceux-ci MA32300B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4843108P 2008-04-28 2008-04-28
US4868908P 2008-04-29 2008-04-29
PCT/US2009/041785 WO2009134711A1 (fr) 2008-04-28 2009-04-27 Anticorps anti-facteur d humanisés et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
MA32300B1 true MA32300B1 (fr) 2011-05-02

Family

ID=40999836

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33342A MA32300B1 (fr) 2008-04-28 2010-11-11 Anticorps anti-facteur d humanises et utilisations de ceux-ci

Country Status (35)

Country Link
US (7) US8273352B2 (fr)
EP (3) EP2283041B1 (fr)
JP (2) JP5636359B2 (fr)
KR (2) KR20130084330A (fr)
CN (2) CN102066419B (fr)
AR (2) AR071510A1 (fr)
AU (1) AU2009241348C1 (fr)
BR (1) BRPI0907701A2 (fr)
CA (2) CA2908470A1 (fr)
CL (2) CL2009001001A1 (fr)
CO (1) CO6331346A2 (fr)
CR (2) CR20170001A (fr)
CY (1) CY1116982T1 (fr)
DK (1) DK2283041T3 (fr)
EC (1) ECSP10010637A (fr)
ES (1) ES2552817T3 (fr)
HK (1) HK1245812A1 (fr)
HR (1) HRP20151259T1 (fr)
HU (1) HUE026349T2 (fr)
IL (3) IL208555A (fr)
MA (1) MA32300B1 (fr)
MX (2) MX2010011342A (fr)
MY (2) MY172433A (fr)
NZ (3) NZ603492A (fr)
PE (2) PE20091783A1 (fr)
PH (1) PH12014500519B1 (fr)
PL (1) PL2283041T3 (fr)
PT (1) PT2283041E (fr)
RS (1) RS54405B1 (fr)
RU (1) RU2488594C2 (fr)
SG (2) SG10201608305SA (fr)
SI (1) SI2283041T1 (fr)
TW (3) TW201819418A (fr)
WO (1) WO2009134711A1 (fr)
ZA (1) ZA201301709B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
CN106084055A (zh) 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
WO2011130377A2 (fr) * 2010-04-15 2011-10-20 Abbott Laboratories Protéines de liaison à la bêta amyloïde
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2012106615A1 (fr) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Procédés et matériaux pour améliorer l'expression d'une protéine fonctionnelle dans des bactéries
KR101966712B1 (ko) 2011-03-25 2019-04-09 인텔 코포레이션 분할가능한 엔진에 의해 인스턴스화된 가상 코어를 이용한 코드 블록의 실행을 지원하는 메모리 프래그먼트
US20150039859A1 (en) * 2011-11-22 2015-02-05 Soft Machines, Inc. Microprocessor accelerated code optimizer
SG11201502076SA (en) 2012-09-19 2015-04-29 Genentech Inc Methods and compositions for preventing norleucine misincorporation into proteins
KR20150095684A (ko) 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
WO2014165271A2 (fr) 2013-03-13 2014-10-09 Neotope Biosciences Limited Immunothérapie contre tau
WO2014151043A1 (fr) 2013-03-15 2014-09-25 Soft Machines, Inc. Procédé d'émulation d'une architecture de drapeau centralisée invitée au moyen d'une architecture de drapeau répartie native
EP3003372B1 (fr) 2013-06-07 2019-10-09 Duke University Inhibiteurs du facteur h du complément
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
MX2016001854A (es) * 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
US20160237146A1 (en) * 2013-10-07 2016-08-18 Massachusetts Eye And Ear Infirmary Methods of Preventing or Reducing Photoreceptor Cell Death
SG11201608868PA (en) * 2014-05-01 2016-11-29 Genentech Inc Anti-factor d antibody variants and uses thereof
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
WO2015200905A2 (fr) 2014-06-28 2015-12-30 Oligasis, Llc Doubles antagonistes de pdgf/vegf
TW201730211A (zh) * 2015-10-30 2017-09-01 建南德克公司 抗因子d抗體及結合物
JP2018536650A (ja) * 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
WO2017075259A1 (fr) * 2015-10-30 2017-05-04 Genentech, Inc. Formulations d'anticorps anti-facteur d
HK1257425A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 测量因子d活性和因子d抑制剂效力的方法
BR112018007703A2 (pt) 2015-10-30 2018-11-06 Genentech Inc anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
SI3368579T1 (sl) * 2015-10-30 2022-04-29 F.Hoffmann-La Roche Ag Tečajni modificirani fragmenti protitelesa in metode priprave
FI3380518T3 (fi) * 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
EP3405577B8 (fr) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions et procédés pour inhiber le facteur d
CN107043422B (zh) * 2016-01-28 2022-01-04 成都康弘生物科技有限公司 抗补体因子D的人源化Fab和人源化抗体及其用途
EP3452507B1 (fr) 2016-05-02 2022-10-19 Prothena Biosciences Limited Immunothérapie anti-tau
WO2018136827A1 (fr) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Compositions à boucle en épingle à cheveux et procédés pour inhiber le facteur d
KR20190129859A (ko) 2017-02-10 2019-11-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-d 인자 항체 및 그의 용도
CN106905431B (zh) * 2017-04-10 2020-01-17 旭华（上海）生物研发中心有限公司 抗人补体d因子的单克隆抗体及其用途
CA3059938A1 (fr) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Anticorps antagonistes du facteur d du complement et leurs conjugues
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CA3092588A1 (fr) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Anticorps anti-il-6 et constructions de fusion et conjugues associes
US12172106B2 (en) 2018-08-09 2024-12-24 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptor
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
WO2025208782A1 (fr) * 2024-04-02 2025-10-09 Linno (Hangzhou) Pharmaceuticals Inc. Fragments d'anticorps se liant au facteur d du complément et leurs utilisations

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
CA2018228C (fr) 1989-06-05 1996-02-27 Nancy L. Parenteau Systemes et milieu de culture cellulaire
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
EP0590058B1 (fr) * 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
EP0604580A1 (fr) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab') 2?
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
CA2140933A1 (fr) 1992-08-21 1994-02-22 Paula M. Jardieu Methode de traitement pour les atteintes dues a la molecule lfa-1
US5861156A (en) 1993-01-08 1999-01-19 Creative Biomolecules Methods of delivering agents to target cells
US5856300A (en) 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US5679564A (en) 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
AU756490B2 (en) 1997-08-26 2003-01-16 Abgenix, Inc. A process for inhibiting complement activation via the alternative pathway
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
DK1481990T3 (da) 1997-11-21 2007-10-01 Genentech Inc A33-beslægtede antigener og deres farmakologiske anvendelser
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
EP3056516A1 (fr) 1998-02-20 2016-08-17 Genentech, Inc. Inhibiteurs d'activation complémentaire
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
WO2000012703A2 (fr) 1998-08-27 2000-03-09 Incyte Pharmaceuticals, Inc. Molecules associees au transport de proteines
IL142794A0 (en) 1998-12-16 2002-03-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL143031A0 (en) 1998-12-22 2002-04-21 Genentech Inc Methods and compositions for inhibiting neoplastic cell growth
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
KR20010103046A (ko) 1999-03-08 2001-11-17 제넨테크, 인크. 면역 관련 질환 치료용 조성물 및 치료 방법
MXPA01009110A (es) 1999-03-11 2002-08-20 Rmf Dictagene Sa Moleculas de adhesion vascular y modulacion de su funcion.
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003514541A (ja) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １８個のヒト分泌タンパク質
CA2391455A1 (fr) 1999-12-01 2001-06-07 Genentech, Inc. Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US6998468B2 (en) 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
DK1287364T3 (da) 2000-04-29 2009-03-02 Univ Iowa Res Found Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
EP2075253A1 (fr) 2000-06-23 2009-07-01 Genentech, Inc. Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse
CA2416538A1 (fr) 2000-07-20 2002-01-31 Genentech, Inc. Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
ATE449791T1 (de) 2000-10-10 2009-12-15 Genentech Inc Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
US20040077575A1 (en) 2002-01-11 2004-04-22 Giordano Giovan Giacomo Inhibition of pathological angiogenesis in vivo
MXPA04001301A (es) 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
US20040152105A1 (en) 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
RU2232991C1 (ru) 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005014849A2 (fr) 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associes a des reponses a des douleurs neuropathiques
WO2005025509A2 (fr) 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methodes et matieres de traitement de maladies et de troubles auto-immuns
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
CA2588270A1 (fr) 2004-11-18 2006-06-15 Yale University Methodes et preparations pour le traitement de troubles oculaires
WO2006071856A2 (fr) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulines comprenant principalement une glycoforme man5glcnac2
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US7695909B2 (en) 2005-06-08 2010-04-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
CN101325963B (zh) 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
DK2500030T4 (en) * 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
CN106084055A (zh) * 2006-11-02 2016-11-09 健泰科生物技术公司 人源化的抗‑d因子抗体
JP2010526555A (ja) 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
EP2283163B1 (fr) 2008-04-18 2015-07-08 Tufts Medical Center Polymorphismes associés à la dégénérescence maculaire liée à l âge et procédés d évaluation du risque pour un patient
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR101719376B1 (ko) 2008-11-05 2017-03-23 제넨테크, 인크. 연령-관련 황반 변성에서 유전자 다형성
WO2010075519A2 (fr) 2008-12-23 2010-07-01 Massachusetts Eye & Ear Infirmary Variantes alléliques associées à la dégénérescence maculaire liée à l'âge avancée
WO2010085542A2 (fr) 2009-01-23 2010-07-29 Novartis Ag Biomarqueurs associés à la dégénérescence maculaire liée à l'âge (dmla)
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
JP5651527B2 (ja) * 2011-05-02 2015-01-14 沖電気工業株式会社 無線端末装置、無線通信システム、プログラムおよび無線通信方法

Also Published As

Publication number Publication date
EP3002295A1 (fr) 2016-04-06
PT2283041E (pt) 2015-11-24
PH12014500519A1 (en) 2017-12-11
IL208555A0 (en) 2010-12-30
MY162350A (en) 2017-06-15
EP2283041A1 (fr) 2011-02-16
CA2720853C (fr) 2015-12-29
CA2908470A1 (fr) 2009-11-05
US20120328613A1 (en) 2012-12-27
PL2283041T3 (pl) 2016-01-29
RU2010148423A (ru) 2012-06-10
TW200944234A (en) 2009-11-01
JP2011521623A (ja) 2011-07-28
AR071510A1 (es) 2010-06-23
AR086272A2 (es) 2013-12-04
MX2018013087A (es) 2020-09-02
EP2283041B1 (fr) 2015-09-02
HUE026349T2 (en) 2016-06-28
IL266039A (en) 2019-06-30
NZ621103A (en) 2015-10-30
KR20110004451A (ko) 2011-01-13
HK1193111A1 (zh) 2014-09-12
IL208555A (en) 2017-09-28
KR101322027B1 (ko) 2013-10-30
RU2488594C2 (ru) 2013-07-27
CL2009001001A1 (es) 2010-05-14
PH12014500519B1 (en) 2019-06-28
US8273352B2 (en) 2012-09-25
RS54405B1 (sr) 2016-04-28
PE20091783A1 (es) 2009-12-04
SG10201608305SA (en) 2016-11-29
CN103724433A (zh) 2014-04-16
ES2552817T3 (es) 2015-12-02
US20140065137A1 (en) 2014-03-06
CN102066419A (zh) 2011-05-18
JP5931008B2 (ja) 2016-06-08
US20160145349A1 (en) 2016-05-26
AU2009241348C1 (en) 2013-03-28
HK1245812A1 (en) 2018-08-31
ZA201301709B (en) 2023-01-25
US20180100024A1 (en) 2018-04-12
TW201437230A (zh) 2014-10-01
HK1147503A1 (en) 2011-08-12
US9676868B2 (en) 2017-06-13
IL253014A0 (en) 2017-08-31
CL2018000537A1 (es) 2018-07-20
DK2283041T3 (da) 2015-12-07
ECSP10010637A (es) 2010-12-30
NZ588457A (en) 2012-12-21
AU2009241348B2 (en) 2012-11-15
SG189756A1 (en) 2013-05-31
US20090269338A1 (en) 2009-10-29
US20190185579A1 (en) 2019-06-20
NZ603492A (en) 2014-05-30
CR20170001A (es) 2017-08-10
CO6331346A2 (es) 2011-10-20
CA2720853A1 (fr) 2009-11-05
TW201819418A (zh) 2018-06-01
TWI558413B (zh) 2016-11-21
CN103724433B (zh) 2015-11-18
US20140212433A1 (en) 2014-07-31
US8614306B2 (en) 2013-12-24
AU2009241348A1 (en) 2009-11-05
HRP20151259T1 (hr) 2015-12-18
BRPI0907701A2 (pt) 2019-12-10
PE20140806A1 (es) 2014-07-17
SI2283041T1 (sl) 2015-12-31
WO2009134711A8 (fr) 2010-10-21
EP3235829A1 (fr) 2017-10-25
WO2009134711A1 (fr) 2009-11-05
TWI616456B (zh) 2018-03-01
JP2013231045A (ja) 2013-11-14
CR11817A (es) 2011-01-13
EP3235829B1 (fr) 2019-05-22
MY172433A (en) 2019-11-25
JP5636359B2 (ja) 2014-12-03
KR20130084330A (ko) 2013-07-24
CN102066419B (zh) 2014-07-02
MX2010011342A (es) 2010-12-06
CY1116982T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MA30163B1 (fr) Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques
MA29439B1 (fr) Derives d'uree d'heteroaryle utilises pour inhiber chk1
MA34120B1 (fr) Composition pharmaceutique
MA45655A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA30252B1 (fr) Vaccin therapeutique
TN2009000551A1 (fr) Nouveaux composes chimiques
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA30632B1 (fr) Anticorps humanisé
MA35114B1 (fr) 1,3-oxazines à titre d'inhibiteurs de bace1 et/ou de bace2
MA52288B1 (fr) Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
MA33726B1 (fr) Composes de dioxyde d'iminothiadiazine comme inhibiteurs de bace, compositions et leur utlisation
MA32621B1 (fr) Traitement de maladie auto-immune et inflammatoire
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
MA32804B1 (fr) Antagonistes d'isonicotinamide des récepteurs de l'orexine
MY162350A (en) Humanized anti-factor d antibodies and uses thereof
MA33815B1 (fr) Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
TNSN07401A1 (fr) Anticorps diriges contre le peptide amyloide-beta, et methodes pour leurs utilisations
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA29366B1 (fr) Therapie antiangiogenique de maladie auto-immune chez des patients qui n'ont pas reagi a une therapie anterieure
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines